Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating that its investigational amylin-based therapies support bone health during weight loss, while once-weekly semaglutide significantly reduces body mass index in children with obesity. Amylin Pipeline Protects Bone Health Substantial weight loss from medication, surgery, or diet can lower bone mass and increase fracture risks. On Tuesday, Novo Nordisk shared...
Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops
Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating that its investigational amylin-based th...
By Dhallo News · November 17, 2026 at 8:19 PM IST
Have feedback on this article?Report error or suggestion
